Share price · ARWR
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ARWR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 9 Nov 2026-15.3%
- 15 Sep 2026-12.4%
- 22 Jul 2026+19.0%
- 10 Jul 2026-9.0%
Nothing announced by ARWR that day or the session before.
- 11 May 2026+6.9%
Nothing announced by ARWR that day or the session before.
- 8 May 2026-6.7%
- 15 Apr 2026+6.4%
Nothing announced by ARWR that day or the session before.
- 7 Jan 2026-7.2%
- 6 Jan 2026+10.8%
- 8 Dec 2025+11.7%
Share of unusual movement by asset
For each asset, the share of ARWR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(16 total)
| Target & Modality | |||
|---|---|---|---|
Plozasiran(Redemplo) | Approved | APOC3RNA / oligonucleotide | Familial Chylomicronemia SyndromeSevere HypertriglyceridemiaCardiovascular Disease / Dyslipidemia Hypertriglyceridemia |
| Phase 3 | SERPINA1RNA / oligonucleotide | Alpha-1 Antitrypsin Deficiency | |
| Phase 3 | LPA gene / apolipoprotein(a) mRNARNA / oligonucleotide | Atherosclerotic Cardiovascular Disease | |
| Phase 3 | ANGPTL3 gene mRNA (hepatic)RNA / oligonucleotide | Homozygous Familial Hypercholesterolemia | |
| Phase 2 | RAGE (receptor for advanced glycation end-products)RNA / oligonucleotide | Asthma | |
| Phase 2 | HBV RNA (X and S transcripts)RNA / oligonucleotide | Chronic Hepatitis B | |
| Phase 2 | HSD17B13RNA / oligonucleotide | MASH / NASH | |
| Phase 1/2 | ALK7 (Activin receptor-like kinase 7)RNA / oligonucleotide | Obesity | |
| Phase 1/2 | Complement C3RNA / oligonucleotide | Complement-Mediated Renal Disease | |
| Phase 1/2 | PCSK9/APOC3RNA / oligonucleotide | Mixed Hyperlipidemia | |
| Phase 1/2 | INHBE (Inhibin beta E chain / Activin E)RNA / oligonucleotide | Obesity | |
| Phase 1/2 | MAPT mRNA (RNAi/ASO)RNA / oligonucleotide | Alzheimer's Disease | |
| Phase 1/2 | DUX4RNA / oligonucleotide | Facioscapulohumeral Muscular Dystrophy | |
| Phase 1/2 | DMPK (dystrophia myotonica protein kinase)RNA / oligonucleotide | Myotonic Dystrophy Type 1 | |
| Phase 1 | Complement factor B (CFB) mRNARNA / oligonucleotide | IgA Nephropathy |
Upcoming events
(20 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
2027 (8)
February 2027 (1)
May 2027 (1)
What to watch
June 2027 (1)
What to watch
July 2027 (1)
What to watch
August 2027 (1)
October 2027 (1)
November 2027 (1)
What to watch
2028 (6)
2029 (3)
2031 (1)
2033 (1)
May 2033 (1)
What to watch
Regulatory and conference events
(8)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $75M | — | $55M+ $1.5B short-term inv. | $194M-$177M operating cash flow | report ↗ |
Arrowhead Pharmaceuticals reported revenue of $75.25M for the quarter ended June 30, 2026, up 171.0% YoY from $27.77M. R&D spend was not disclosed; cash and equivalents were $54.76M. The company recorded a net loss of $194.28M, equal to its quarterly net burn of $194.28M.
Key developments included continued U.S. commercial momentum for REDEMPLO, with new marketing authorizations from the European Commission and the Australian TGA for familial chylomicronemia syndrome. Topline results from the Phase 3 SHASTA-3 and SHASTA-4 trials of plozasiran met their primary and all prespecified secondary endpoints, including a 78% reduction in acute pancreatitis events; detailed results are scheduled for ESC 2026. Enrollment completed in the Phase 3 YOSEMITE trial of zodasiran, with study completion anticipated in mid-2027. The company also licensed ARO-PNPLA3 to Madrigal Pharmaceuticals for up to $975M in milestones and acquired an FDA priority review voucher for a planned plozasiran sNDA.
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $74M | — | $189M+ $1.6B short-term inv. | $133M$84M operating cash flow | report ↗ |
| 2025-Q4 | $264M | — | $202M+ $715M short-term inv. | —$13M operating cash flow | report ↗ |
| 2025-Q2 | $28M | $162M | $130M+ $771M short-term inv. | $175M-$155M operating cash flow | report ↗ |
| 2025-Q1 | $543M | $133M | $186M+ $912M short-term inv. | —$460M operating cash flow | report ↗ |
| 2024-Q4 | $2.5M | $137M | $54M+ $499M short-term inv. | $173M-$146M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $152M | $69M+ $367M short-term inv. | $171M-$115M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $101M | $128M+ $395M short-term inv. | $125M-$92M operating cash flow | report ↗ |
| 2023-Q4 | $3.5M | $116M | $58M+ $162M short-term inv. | $133M-$118M operating cash flow | report ↗ |
| 2023-Q2 | $16M | $95M | $105M | $103M-$21M operating cash flow | report ↗ |
| 2023-Q1 | $146M | $75M | $135M | —-$32M operating cash flow | report ↗ |
| 2022-Q4 | $63M | $84M | $202M | $41M-$76M operating cash flow | report ↗ |
| 2022-Q2 | $32M | $72M | —+ $0 short-term inv. | $72M-$69M operating cash flow | report ↗ |
| 2022-Q1 | $152M | $76M | —+ $123M short-term inv. | —$63M operating cash flow | report ↗ |
| 2021-Q4 | $27M | $66M | —+ $126M short-term inv. | $63M-$61M operating cash flow | report ↗ |
Annual history (6 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-FY | $451M | $739M | $63M+ $1.1B short-term inv. | $181M-$272M operating cash flow | report ↗ |
View 5 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $829M | — | $227M+ $693M short-term inv. | $0.4M$180M operating cash flow | report ↗ |
| 2024-FY | $3.5M | $506M | $103M+ $578M short-term inv. | $150M-$463M operating cash flow | report ↗ |
| 2023-FY | $241M | $353M | $111M+ $293M short-term inv. | $51M-$154M operating cash flow | report ↗ |
| 2022-FY | $243M | $297M | $108M+ $0 short-term inv. | $44M-$136M operating cash flow | report ↗ |
| 2021-FY | $138M | $206M | $184M+ $127M short-term inv. | $35M$171M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 64 sales ($37.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-18 | PERRY MICHAEL S · director | Open-market sale | 11,600 | $87.30 | $1.0M | Form 4 |
| 2026-08-18 | OLUKOTUN ADEOYE Y · director | Open-market sale | 2,000 | $86.96 | $174K | Form 4 |
| 2026-06-15 | Cohen Matthew Gregory · director | Award / grant | 11,882 | — | — | Form 4 |
| 2026-05-12 | Lu Hongbo · director | Open-market sale | 2,970 | $76.88 | $228K | Form 4 |
| 2026-04-23 | Hamilton James C · Chief Medical Officer | Open-market sale | 10,000 | $75.00 | $750K | Form 4 |
| 2026-04-22 | Apel Daniel Joseph · Chief Financial Officer | Open-market sale | 3,208 | $70.11 | $225K | Form 4 |
| 2026-04-22 | Apel Daniel Joseph · Chief Financial Officer | Open-market sale | 1,157 | $70.45 | $82K | Form 4 |
| 2026-04-22 | Apel Daniel Joseph · Chief Financial Officer | Open-market sale | 8,730 | $71.92 | $628K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 431 reporting institutions held 120.7M shares ($7.4B, 85.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 18,161,519 | $1.1B |
| 2 | Avoro Capital Advisors LLC | 10,699,999 | $670.9M |
| 3 | FMR LLC | 7,266,652 | $455.6M |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 7,146,136 | $448.1M |
| 5 | STATE STREET CORP | 6,496,130 | $407.3M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 6,032,416 | $378.2M |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 4,278,828 | $274.5M |
| 8 | FRED ALGER MANAGEMENT, LLC | 3,342,493 | $209.6M |
| 9 | Invesco Ltd. | 3,280,647 | $205.7M |
| 10 | Vestal Point Capital, LP | 2,275,000 | $142.6M |
| 11 | BAKER BROS. ADVISORS LP | 1,992,783 | $124.9M |
| 12 | GOLDMAN SACHS GROUP INC | 1,739,923 | $109.1M |
| 13 | NORTHERN TRUST CORP | 1,655,837 | $103.8M |
| 14 | Siren, L.L.C. | 1,615,476 | $101.3M |
| 15 | DEERFIELD MANAGEMENT COMPANY, L.P. | 1,573,297 | $98.6M |